Comparison and modulation of angiogenic responses by FGFs, VEGF and SCF in murine and human fibrosarcomas

The effects of angiogenic growth factors on the growth, vascular architecture and the downstream cytokine signaling of sarcomas are unknown. These are of potential great importance since sarcoma. like endothelium. is of mesodermal origin and therefore could grow in response to these factors. Three human sarcomas (leiomyosarcoma SK-LMS-1. liposarcoma SW872 and fibrosarcoma SW684) and one murine fibrosarcoma (KET) were grown in nude and C3H/He mice, respectively. Tumor structural vessels, perfused vessels and hypoxia were quantified immunohistochemically. Fast-growing murine KHT tumors had a markedly higher number of structural vessels compared with the human sarcomas. In both murine and human sarcomas. approximately half of the total structural vessels were perfused. and the numbers of per-fused vessels decreased with increasing tumor volume. In vitro, basal rnRNA expression of several angiogenic growth factors and their receptors differed between two of the human sarcoma cell lines, SK-LMS-1 and SW872. Compared with SK-LMS-1, untreated SW872 cells had higher levels of mRNA expression for FGH11, FGF14, angiopoietin. CD105 and VEGFR1. Two sarcoma cell lines were also treated with 10 ng/ml of six angiogenic growth factors (FGF1, FGF2, FGF7, FGF10. VEGF and SCF) for 24 h. and mRNA expression of endogenous FGF family members (FGF1, FGF2. FGF10, FGF11. FGF13 and FGF14) were quantitatively measured using RNase protection at various times following treatments. Again, SW872 cells were more responsive to exogenous growth factor treatment compared with SK-LMS-1 cells in terms of the elevation of endogenous FGF mRNA expression. In the SW872 cells. all of the exogenous angiogenic growth factor treatments, except for VEGF. upregulated endogenous FGF1, FGF2 and FGF14 mRNA expression. The SK-LMS-1 cells, in contrast, only responded to exogenous FGFI. FGF7 and FGF10, but did not respond to VEGF. (C) 2002 Elsevier Science Inc. All rights reserved.